Samuel Clarke

Samuel Clarke

Company: Precision NanoSystems

Job title: Director - R&D


Seminar: Novel Lipid Nanoparticle Platform Enables RNA Delivery for Different Applications in Genetic Medicine

  • RNA can be designed to silence, express, and edit specific genes providing a flexible and powerful approach to treating disease
  • RNA are large molecules that require nanoparticles for delivery to target tissues and cells
  • We have developed the GenVoyTM lipid nanoparticle platform, comprised of proprietary ionizable lipids and compositions designed for specific applications in genetic medicine
  • We showcase data in the areas of vaccines, gene therapies and cell therapies to demonstrate the versatility of the GenVoyTM platform to accelerate development of different genetic medicines

Day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.